ERBB2 and breast carcinoma: Previous study showed that AZD8931 is an equipotent, reversible inhibitor of EGFR, HER2 and HER3 signaling with potent in vitro inhibition of EGFR, HER2 and HER3 phosphorylation in breast cancer and squamous carcinoma cells[16].